
This study investigated the impact of early treatment on long-term outcomes in patients with a first demyelinating event and early multiple sclerosis (MS). 580 patients receiving disease modifying drugs were categorized by treatment timing: very early (6 months, N=194), intermediate (6.1-16 months, N=192), and late (16.1 months, N=194). A Magnetic Resonance Score (MRS) was devised based on MRI findings. Early treatment was linked to reduced risk of EDSS 3.0, secondary progressive MS, and sustained progression compared to late treatment. Patients in the very early group exhibited lower disability progression rates and severity. MRI findings reinforced treatment decisions. This Class III evidence highlights the benefits of early MS treatment after initial demyelination.
Like
Save
Share